Physician profile
Adam Byrd
NPI 1689969735
$2,275.37
in general payments reported to CMS, 2019-2025
15 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $45.69 · 2021: $319 · 2022: $632 · 2023: $181 · 2024: $151 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $536.20 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $480.99 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $235.10 | 2021-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $194.60 | 2025 | Tremfya |
| Pfizer INC. | $175.33 | 2019-2023 | |
| Organogenesis INC. | $140.17 | 2023 | Puraply |
| E.R. Squibb & Sons, L.L.C. | $119.36 | 2022 | |
| Ucb, INC. | $95.61 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $90.88 | 2022-2024 | Ebglyss, Taltz, Zepbound |
| Janssen Biotech, INC. | $61.46 | 2021-2024 | Tremfya |
| Leo Pharma INC. | $60.08 | 2022-2025 | Adbry |
| Incyte Corporation | $37.67 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.37 | 2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $16.15 | 2021 | |
| Dusa Pharmaceuticals, INC. | $15.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.